Drug Profile
Research programme: epigenetic targeted therapeutics - Ignyta
Alternative Names: Autoimmune disorder therapeutics - Ignyta; Cancer therapeutics - Ignyta; Immuno-oncology therapeutics - Ignyta; Spark-1; Spark-1 Rx/Dx Program; Spark-2; Spark-2 Rx/Dx Program; Spark-3; Spark-3 Rx/Dx ProgramLatest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Actagene-Oncology; Ignyta
- Developer Ignyta
- Class Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer